Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Upstream Bio, Inc. ( (UPB) ) has issued an update.
On March 26, 2026, Upstream Bio, Inc. entered into a sales agreement with Leerink Partners LLC to establish an at-the-market equity program for its common stock. Under this arrangement, the company may, but is not obligated to, sell up to $150 million of shares from time to time through Leerink Partners on Nasdaq or other existing trading markets.
Leerink Partners will act as sales agent, using commercially reasonable efforts and receiving a commission of up to 3.0% of gross proceeds from each sale. The flexible structure allows either party to suspend or terminate the program, providing Upstream Bio with incremental access to capital that can influence its funding strategy and shareholder dilution over time.
The ATM offering is being conducted under Upstream Bio’s automatic shelf registration statement on Form S-3ASR, which became effective on November 5, 2025. A related prospectus supplement and a legal opinion from Goodwin Procter LLP, both dated March 26, 2026, support the validity and regulatory framework of the shares to be issued under this program.
The most recent analyst rating on (UPB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Upstream Bio, Inc. stock, see the UPB Stock Forecast page.
Spark’s Take on UPB Stock
According to Spark, TipRanks’ AI Analyst, UPB is a Neutral.
The score is driven primarily by strong technical momentum (price above key moving averages with positive MACD and supportive RSI). This is tempered by weak financial performance typical of an early-stage biotech—expanding losses and worsening cash burn—despite a low-debt balance sheet. Valuation is also constrained by negative earnings (negative P/E) and no stated dividend yield.
To see Spark’s full report on UPB stock, click here.
More about Upstream Bio, Inc.
Upstream Bio, Inc. is a publicly traded company listed on the Nasdaq Global Select Market, operating within the broader U.S. capital markets ecosystem. The company issues common stock with a par value of $0.001 per share and accesses equity financing through registered offerings under an automatic shelf registration statement filed with the U.S. Securities and Exchange Commission.
Average Trading Volume: 1,306,028
Technical Sentiment Signal: Strong Sell
Current Market Cap: $511.7M
Find detailed analytics on UPB stock on TipRanks’ Stock Analysis page.